Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa

First subject dosed in Phase I study to evaluate safety and tolerability of…


Infex Awarded Biomedical Catalyst Grant For COV-X Project

Alderley Park, Cheshire, U.K - Infex Therapeutics, a leading anti-infectives…


COVID-19 Pandemic Triggers Upsurge in MBL Infections

New research has discovered that the ongoing COVID-19 pandemic has triggered a…